Research programme: neurological disorder therapeutics - Affichem

Drug Profile

Research programme: neurological disorder therapeutics - Affichem

Alternative Names: AF 243; AF 250s

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affichem
  • Class Sterols
  • Mechanism of Action Cell differentiation stimulants; Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hearing loss
  • Discontinued Alzheimer's disease; Brain injuries; Parkinson's disease; Retinal disorders

Most Recent Events

  • 28 Jul 2016 Preclinical development is ongoing for Hearing loss in France (Affichem pipeline, July 2016)
  • 28 Jul 2016 Discontinued - Preclinical for Parkinson's disease in France (unspecified route)
  • 28 Jul 2016 Discontinued for Alzheimer's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top